22.66MMarket Cap
LossP/E TTM
Key Figures
0.380Open
0.385High
88.33KVolume
LossP/E TTM
9.55P/E Dynamic
--Dividend TTM
0.14%Turnover Ratio
0.350Prev. Close
0.352Low
22.27KTurnover
LossP/E Static
2.51P/B
0.00%Div Yield TTM
-25.94%ROA
1.39052wk High
1.60Volume Ratio
-20.72MNet Profit
62.79MShares
-0.1891EPS TTM
1.37Beta
-141.59%ROE
0.43552wk Low
9.34%Amplitude
69.16%Gross Margin
22.66MMarket Cap
-2.21Reward/Risk
4.63%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Cytosorbents Corp's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 121 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.88.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cytosorbents Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Cytosorbents Corp Highlights
StrengthsRisks
Cytosorbents Corp News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Intuitive Surgical Inc
ISRG
35
Boston Scientific Corp
BSX
34
Edwards Lifesciences Corp
EW
33
Thermo Fisher Scientific Inc
TMO
29
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cytosorbents Corp Info
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Ticker SymbolCTSO
CompanyCytosorbents Corp
CEOChan (Phillip P)
Websitehttps://cytosorbents.com/
Shareholders
FAQs
What is the current price of Cytosorbents Corp (CTSO)?
The current price of Cytosorbents Corp (CTSO) is 0.37.
What is the symbol of Cytosorbents Corp?
The ticker symbol of Cytosorbents Corp is CTSO.
What is the 52-week high of Cytosorbents Corp?
The 52-week high of Cytosorbents Corp is 1.39.
What is the 52-week low of Cytosorbents Corp?
The 52-week low of Cytosorbents Corp is 0.43.
What is the market capitalization of Cytosorbents Corp?
The market capitalization of Cytosorbents Corp is 22.95M.
Is Cytosorbents Corp (CTSO) currently rated as Buy, Hold, or Sell?
According to analysts, Cytosorbents Corp (CTSO) has an overall rating of signal_hold, with a price target of 2.88.
What is the Earnings Per Share (EPS TTM) of Cytosorbents Corp (CTSO)?
The Earnings Per Share (EPS TTM) of Cytosorbents Corp (CTSO) is -0.13.
